November 8, 2014
Notes: Nassar, Dany
Research Support, Non-U.S. Gov’t
J Invest Dermatol. 2013 Feb;133(2):371-6. doi: 10.1038/jid.2012.279. Epub 2012 Aug 30.
Author Address: INSERM U938, Centre de Recherche Saint Antoine, Paris, France.
Reference Type: Journal Article
Record Number: 4539Author: Ng, L. C., Lee, Y. Y., Lee, C. K. and Wong, S. M.
Title: A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia
Journal: Int J Dermatol
Short Title: A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia
Alternate Journal: International journal of dermatology
ISSN: 1365-4632 (Electronic)
Accession Number: 23278617
Dermatologic Agents/*adverse effects
Drug-Induced Liver Injury/*etiology
Severity of Illness Index
Tertiary Care Centers
Abstract: BACKGROUND: Methotrexate (MTX) is a common and efficacious systemic agent used for the treatment of moderate to severe psoriasis. Nevertheless, its use is associated with the risk of hepatotoxicity. This study was performed to study the association of MTX dose with regards to hepatotoxicity as evidenced by deranged transaminases. METHODS: This was a retrospective review of patients with psoriasis on MTX from 2000 to 2009 at the outpatient dermatology clinic, University Malaya Medical Centre (UMMC). We analyzed patients’ demography, serial laboratory investigations, liver ultrasounds, and liver biopsies of patients on MTX. RESULTS: Sixty-six of 710 (9.30%) patients with psoriasis were prescribed MTX throughout the 10-year period. Among them 57.6% developed deranged transaminases, with six requiring MTX withdrawal due to hepatotoxicity. The mean cumulative dose of MTX at the detection of liver enzyme derangement was 552.3 +/- 596.1 mg. CONCLUSION: A high proportion of patients on MTX had deranged transaminases. However, the number of serious events was low. We concluded from this study that the use of MTX is relatively safe in patients with moderate to severe psoriasis.